Source:http://linkedlifedata.com/resource/pubmed/id/11949624
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2002-4-11
|
| pubmed:abstractText |
We analyzed a series of adrenocortical neoplasms to compare the clinicopathologic features and the expression of insulin-like growth factor-2 (IGF-2) in adrenocortical adenomas and carcinomas. IGF-2 is a growth factor commonly expressed in many tumors including adrenal cortical and medullary neoplasms. Formalin-fixed paraffin-embedded tissues from 64 adrenocortical adenomas and 67 adrenocortical carcinomas were analyzed. The carcinomas were histologically graded from 1 to 4 based on mitotic activity and necrosis. Tumor weight, size, and follow-up information were obtained by chart review. Expression of IGF-2 was detected by immunohistochemistry with the avidin-biotin-peroxidase complex method and a monoclonal antibody against IGF-2. Adrenocortical carcinomas were larger (mean: 13.1 cm, 787 g) than adenomas (mean: 4.2 cm, 52 g) (p < 0.001). Inpatients with adrenocortical carcinomas, high tumor grade (3 or 4) (p = 0.01) was associated with decreased survival. Expression of IGF-2 was higher in adrenocortical carcinomas than in adenomas (p < 0.001). These results show that tumor size and weight along with expression of IGF-2 protein are useful features to assist in distinguishing between adrenocortical adenomas and carcinomas, and that high tumor grade is a predictor of survival in adrenocortical carcinomas. However, single immunohistochemical markers such as IGF-2 or single histopathologic features cannot by themselves separate adrenocortical adenomas from carcinomas, and a combination of clinical, gross, and microscopic features are needed to establish the diagnosis in difficult cases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1046-3976
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
429-35
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11949624-Adolescent,
pubmed-meshheading:11949624-Adrenal Cortex Neoplasms,
pubmed-meshheading:11949624-Adrenocortical Adenoma,
pubmed-meshheading:11949624-Adrenocortical Carcinoma,
pubmed-meshheading:11949624-Adult,
pubmed-meshheading:11949624-Aged,
pubmed-meshheading:11949624-Aged, 80 and over,
pubmed-meshheading:11949624-Diagnosis, Differential,
pubmed-meshheading:11949624-Female,
pubmed-meshheading:11949624-Humans,
pubmed-meshheading:11949624-Immunoenzyme Techniques,
pubmed-meshheading:11949624-Insulin-Like Growth Factor II,
pubmed-meshheading:11949624-Male,
pubmed-meshheading:11949624-Middle Aged,
pubmed-meshheading:11949624-Mitosis,
pubmed-meshheading:11949624-Necrosis,
pubmed-meshheading:11949624-Survival Analysis,
pubmed-meshheading:11949624-Survival Rate
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms.
|
| pubmed:affiliation |
Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, 200 First Street SW, Rochester, NY 55905, USA.
|
| pubmed:publicationType |
Journal Article
|